SUNNYVALE, California,
November 26, 2015 /PRNewswire/ --
Erasmus MC Team Hosts Clinicians from
Around-the-World at Fully-Subscribed Course
Accuray Incorporated (Nasdaq: ARAY) announced the second course
of the European School of Robotic Stereotactic Radiotherapy at
Erasmus MC Center Institute, Rotterdam,
The Netherlands, following the course's successful
inauguration in June 2015. The
objectives of this School are to:
- Increase awareness of stereotactic body radiation therapy
(SBRT) among the radiation oncology and medical physics
communities;
- Share SBRT knowledge and real-world experience using the
CyberKnife® M6™ System; and
- Facilitate CyberKnife use for new applications with experienced
users.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://photos.prnewswire.com/prnh/20151126/291247 )
"Erasmus MC Cancer Institute has a long history with Accuray.
Working together, we are helping to change the way that cancer is
treated," said Dr. Joost Nuyttens,
M.D., Ph.D., Radiation Oncologist at Erasmus MC Cancer Institute.
"Our Center's extensive technical research and clinical experience
with the CyberKnife System have enabled us to experience first-hand
the benefits that stereotactic radiotherapy offers to cancer
patients. Accuray's support of the School enabled us to share our
knowledge with clinicians worldwide through a peer-to-peer
forum."
"Stereotactic" in Greek means "movement in space" and refers to
3D workspace to locate the tumor or target of a radiation dose.
SBRT precisely targets the tumor to receive a maximum amount of
radiation while sparing surrounding healthy tissue from radiation
exposure. SBRT is a non-invasive treatment that does not require
surgery and reduces the risks of complications sometimes associated
with conventional surgery.
Accuray has been working with Erasmus MC Cancer Institute since
the Center installed its first CyberKnife System in 2004. The
Center was the third site in the EIMEA (Europe, India, Middle
East, and Africa) region to
install a CyberKnife System. To date, more than 2,000 patients,
including those with brain, spine, lung, liver, and prostate cancer
have been treated with the two CyberKnife Systems at Erasmus
MC.
"Erasmus MC Cancer Institute has reported an expected growth of
21% for SBRT treatment volume between 2012 to 20171. As one of the
world's foremost academic oncology centers, this Institute is an
important partner for us in advancing the use of SBRT," said Lionel
Hadjadjeba, senior vice president, and president, worldwide
commercial operations at Accuray. "The European School will
contribute to improve the understanding of the added clinical value
of robotic stereotactic radiotherapy using the CyberKnife System.
With the support of hospitals like Erasmus MC Cancer Institute,
Accuray is offering precise, innovative radiation oncology
treatments to more cancer patients".
1Reference: ©2013 The Advisory Board Company, Hospital
Outpatient Department http://www.advisory.com
About Erasmus MC Cancer Institute
Erasmus MC is one of the largest and most authoritative
scientific University Medical Centers in the Netherlands. 11,250 staff members,
including almost 1,400 students, work within the core tasks of
patient care, education, and scientific research on the continuous
improvement and enforcement of individual patient care and social
healthcare. They develop high-level knowledge, pass this on to
future professionals, and apply it in everyday patient care. Over
the next five years, Erasmus MC aims to grow into one of the
leading international medical institutes. Erasmus MC is part of the
Dutch Federation of University Medical Centers (NFU).
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to market awareness,
education, adoption and acceptance, clinical results, patient
outcomes and Accuray's leadership position in radiation oncology
innovation and technologies. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially from expectations, including but not limited to
the risks detailed under the heading "Risk Factors" in the
company's report on Form 10-K, filed on August 28, 2015, the company's report on Form
10-Q, filed on November 5, 2015, and
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.